Cancer remains a key health priority in the EU, but research funding for bladder cancer (BC) ranks very low despite its high prevalence and very high lifetime costs. We highlight policy areas that need to be addressed in Europe for better BC awareness and diagnostic tools to improve early detection. In addition, funding is needed for more research into gender differences in BC to improve care, treatment, and outcomes for all patients with BC.